Introducing BCOP Sprint
NEW! Timely BCOP Learning with Your Time In Mind
Sometimes all you have is 30 minutes to spare. With BCOP Sprint, that's all the time you need.
HOPA introduces BCOP Sprint, new education programming where you can earn BCOP CEs and take a deep dive into the latest developments in hem/onc pharmacy – all in just 30 minutes. Throughout the year, BCOP Sprint's 30-minute sessions will alternate between hyper-specialized and late-breaking hematology and solid malignancy topics, "drilling down" to real-time information.
BCOP Sprint 2026 Session 1
"UnPACCing Treatment of Uncommon EGFR Mutations"
- When: Wednesday, August 5, 2026, at 1 p.m. CT via Zoom
- Cost: $20 for HOPA members, $26 for non-members
- BCOP Credits: 0.5
Course Description
This presentation will provide an overview of uncommon EGFR mutations in non-small cell lung cancer, focusing on PACC mutations. We will review a structure-based classification framework for EGFR mutations and how this influences drug binding, treatment sensitivity, and therapeutic decision making. Participants will review current guidelines as well as emerging clinical evidence for the first line treatment of EGFR PACC mutations, including novel agents. Real world data, clinical trial data, and a case example will be used to highlight practical considerations in treatment selection and unmet needs in this patient population.
Learning Objectives
- Outline how structure-based classification of EGFR mutations can impact treatment selection for patients
- Explain the treatment landscape for first line treatment options in patients with EGFR PACC mutations, and including emerging and novel treatment options
There will be 0.5 ACPE and BCOP credits available for this session.
Presenter
Amanda S. Cass is a clinical pharmacist specialist in the Thoracic Oncology Clinic at Vanderbilt University Medical Center. In her role, she provides expert pharmaceutical care within the Thoracic Oncology Clinic, focusing on the management of lung cancers and contributing to the advancement of oncology pharmacy practice.
She received her Doctorate of Pharmacy from the University of Kentucky College of Pharmacy in 2016 and subsequently completed her Pharmacy Practice Residency at Grady Health System and became a Board Certified Pharmacotherapy Specialist in 2017. In 2018, she completed her Oncology Pharmacy Residency at the University of North Carolina Medical Center and became a Board Certified Oncology Specialist in 2019.
Beyond her clinical responsibilities, Dr. Cass contributes to the oncology pharmacy community through education and research. She serves as a preceptor for the Outpatient Thoracic Oncology Rotation at VUMC, mentoring pharmacy residents and students. Her scholarly work includes publications on targeted therapies used to treat NSCLC and managing their adverse effects, such as strategies to address diarrhea associated with EGFR tyrosine kinase inhibitors. Additionally, she has participated in continuing education programs, discussing topics like DLL3-targeting bispecific T-cell engager (BiTE) therapy in SCLC, molecular mutations in NSCLC, and use of immunotherapy in NSCLC.
